Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists

Case ID:

C04522

Unmet Need
The recent breakthroughs in immuno-oncology have changed the way that researchers think about treating autoimmune diseases and cancer by modulating the immune system. Regulatory T cells (Treg) limit autoimmunity but also attenuate the potency of antitumor immunity. Enhancement of Treg function could treat autoimmune diseases while the inhibition or elimination of Treg cells could enhance immunotherapy of cancer and infectious diseases.

Technology Overview
Johns Hopkins researchers have identified a Treg specific receptor named neuritin. Neuritin is highly expressed in Treg cells and can bind activated dendritic cells (DCs). When neuritin is over-expressed on T cells it can inhibit both DC cytokine production and antigen presentation which in turn limits the immune response. These findings identify neuritin as a Treg specific surface molecule able to affect DC function. This invention centers on the manipulation of Tregs and DCs via neuritin receptor molecule to enhance immunotherapy of autoimmune diseases, cancers and infectious diseases as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplantation and adoptive transfer. Targeting the neuritin receptor with monoclonal antibodies or therapeutic drugs may provide effective clinical treatment in a number of disease indications or bone marrow transplantation.

Stage of Development
Animal data is available.

Publications
JJ Barbi et al. J Immunol, 2016, 196 (1 Supplement) 58.12

Patent Information:

Title	App Type	Country	Serial No.	Patent No.	File Date	Issued Date	Expire Date	Patent Status
Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists	DIV: Divisional	Japan	2016-83897		9/11/2006			Pending
Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists	PCT: Patent Cooperation Treaty	Japan	2008-530022		9/11/2006			Pending
Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists	PCT: Patent Cooperation Treaty	Australia	2006287315	2006287315	9/11/2006	6/6/2013	9/11/2026	Granted
Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists	DIV: Divisional	European Patent Office	16152994.6		9/11/2006			Pending
Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists	PCT: Patent Cooperation Treaty	Japan	2013-239723	6019334	9/11/2006	10/14/2016	9/11/2026	Granted
Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists	PCT: Patent Cooperation Treaty	Canada	2,621,992	2,621,992	9/11/2006	8/4/2020	9/11/2026	Granted

Direct Link:

https://jhu.technologypublisher.com/technology/29002

Inventors:

Category(s):

Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics,

Get custom alerts for techs in these categories/from these inventors:

Subscribe for JHTV Updates

For Information, Contact:

Jeanine Pennington

jpennin5@jhmi.edu

410-614-0300

Save This Technology:

Bookmark this page

Download as PDF